Results 21 to 30 of about 467,398 (215)

The Robustness of Pathway Analysis in Identifying Potential Drug Targets in Non-Small Cell Lung Carcinoma [PDF]

open access: yes, 2014
The identification of genes responsible for causing cancers from gene expression data has had varied success. Often the genes identified depend on the methods used for detecting expression patterns, or on the ways that the data had been normalized and ...
Ian Bailey   +3 more
core   +1 more source

Long noncoding nature brain-derived neurotrophic factor antisense is associated with poor prognosis and functional regulation in non–small cell lung caner

open access: yesTumor Biology, 2017
In this study, we evaluated the prognostic potential and functional regulation of human nature antisense, brain-derived neurotrophic factor antisense, in non–small cell lung cancer.
MingJing Shen   +5 more
doaj   +1 more source

Durable response to durvalumab‐based immunochemotherapy in small‐cell lung carcinoma transformation from EGFR‐mutant non–small cell lung cancer: A case report

open access: yesThoracic Cancer, 2022
Combined small‐cell lung carcinoma (C‐SCLC) is small‐cell lung carcinoma (SCLC) with added non–small‐cell morphology. We report a case of epidermal growth factor receptor (EGFR) mutation‐positive C‐SCLC in an 84‐year‐old patient with metastatic brain ...
Yu‐Chung Li
doaj   +1 more source

The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. [PDF]

open access: yes, 2009
BACKGROUND: Extrapulmonary small cell carcinoma (EPSCC) is a rare cancer and few studies describe its epidemiology. Our objectives were to compare the incidence and survival of EPSCC in South East England with small cell carcinoma of the lung (SCLC), to ...
Jack, Ruth H   +18 more
core   +1 more source

Predictive testing in non-small cell lung carcinoma

open access: yesKlinicka onkologie, 2021
Predictive testing is a crucial part of the complete diagnostic process of non-small cell lung cancer (NSCLC) and a necessary requirement in order to determine proper course of treatment. However, the possibilities of testing and the spectrum of examined markers are quickly evolving as a result of the progress in diagnostic and therapeutic ...
P, Dundr   +4 more
openaire   +2 more sources

MYC is a metastasis gene for non-small-cell lung cancer. [PDF]

open access: yes, 2009
Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Christian Korn   +26 more
core   +1 more source

Immunotherapy of lung cancer: An update [PDF]

open access: yes, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A.   +15 more
core   +1 more source

The crosstalk between p38 and Akt signaling pathways orchestrates EMT by regulating SATB2 expression in NSCLC cells

open access: yesTumor Biology, 2017
Epithelial–mesenchymal transition is a crucial event for metastasis and could be mediated by several pathways such as phosphoinositide 3-kinase/Akt, mitogen-activated protein kinases, as well as many epigenetic regulators.
Hakan Kucuksayan, Hakan Akca
doaj   +1 more source

EGFR mutation testing in non-small cell lung cancer (NSCLC)

open access: yesJournal of Infection and Public Health, 2012
Summary: Lung carcinoma is subdivided into small cell carcinoma and non-small cell carcinoma (NSCLC). NSCLC is heterogeneous group of carcinomas and accounts for 70–80% of lung cancer. NSCLC is further divided into adenocarcinoma, squamous cell carcinoma,
Fouad Al Dayel
doaj   +1 more source

KAN0438757: a novel PFKFB3 inhibitor that induces programmed cell death and suppresses cell migration in non-small cell lung carcinoma cells . [PDF]

open access: yesBiotechnologia Acta, 2023
Aim. PFKFB3 is glycolytic activators that is overexpressed in human lung cancer and plays a crucial role in multiple cellular functions including programmed cell death.
Deniz Özdemir   +2 more
doaj  

Home - About - Disclaimer - Privacy